We are buying 300 shares of Bristol Myers Squibb at roughly $55.44. In addition, we are selling 100 shares Starbucks at roughly $111.48. Following the trades, Jim Cramer’s Charitable Trust will own 1,800 shares of BMY, increasing its weighting to about 2.7% from about 2.25% and 1,000 shares of SBUX, decreasing its weighting to about 3% from about 3.35%. Now that our trading restrictions have cleared, we’re making a couple of trades we wanted to do last week. Our restrictions prevent us from trading a stock for 72 hours after Jim Cramer mentions it on CNBC TV. First up, we are adding to our position in Bristol Myers Squibb. Shares of the drugmaker have pulled back pretty aggressively over the past few sessions, falling from $59.71 before last week’s earnings report to about $55 on Monday. The slide has erased all of its 2025 gains. Even though the company posted a strong fourth-quarter revenue and adjusted earnings per share beat, the stock got hit when management provided light annual guidance for the top and bottom lines. After combing through the results, we attributed most of the difference between the company’s guidance and the Wall Street consensus to generic competition pressuring Revlimid sales and greater headwinds from foreign exchange. Since these two factors don’t impact our thesis, which is largely centered around sales of recently approved schizophrenia drug Cobenfy, we called the sell-off a buying opportunity. A pair of impactful Cobenfy trial readouts are due later this year — adjunctive schizophrenia in the first half of 2025 and Alzheimer’s disease psychosis in the second half — creating multiple catalysts that could push the drug’s projected sales higher. Plus, when you factor in a low price-to-earnings valuation and 4.4% dividend yield, we remain buyers. As for Starbucks, we downgraded our rating to a hold-equivalent 2 on last Wednesday’s Homestretch and said we would book profits with a small sale if not for our restrictions. Shares of the coffee chain have finally found a groove under the leadership of CEO Brian Niccol, a turnaround artist and one of the most bankable executives in the fast-food and fast-casual spaces. But we know turnarounds are difficult and results may not always improve in a linear fashion. Things can get bumpy at times. That’s why we said it was prudent to lock in some big gains. This is our first sale since Niccol as CEO, and it’s been a great run. Shares are up more than 20% year to date and more than 40% since right before Niccol was named CEO in August 2024. From this sale, we will realize a gain of about 30% on Starbucks stock purchased in August 2022. (Jim Cramer’s Charitable Trust is long BMY and SBUX. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
We’re adding to our position in a sliding stock and booking profits in a 2025 winner
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City.
Spencer Platt | Getty Images
This article was originally published by Cnbc.com. Read the original article here.